reduc estim iq acquisit well
cs global pharma biotech
zolgensma learn fda advers event report
commentari still point stabil
med-tech recap preview
new robot hit mark tct reinforc confid
tavr nass featur new product innov
evan weekli dose therapi
food thought alexa may take order
someth chew foodservic distributor provid intra-q updat
amazon channel tradit food retail vice versa
lean weekend
reason less neg janu henderson meet ceo
c-level field point discuss
opin open
colorect patient
china coal price limit impact solar demand
public contain summari recent credit suiss research report bring notabl research attent full report summari
certif legal entiti disclosur inform statu non-u analyst equiti research disclosur click
price month
reduc estim iq
acquisit well cost
lower ep estim vs con driven
per share consult legal cost iq deal ii
interest expens note issu sept deal-
relat cost financ upcom matur also rais segment cost
addit season higher cost previous alloc corpor
prior estim season higher segment expens pru guidanc
call season higher cost half corpor half
revis come top recent estim reduct
expect ep guid impact
capit market share repurchas previous lower ep estim
reflect anticip well usfw cost weaker
outlook pru individu life gibraltar segment
rais ep estim estim chang credit
guid ep accret iq deal partial off-set
higher interest expens recent debt issuanc alloc deal
iq assumpt line guid oper margin
increment cost save annual amort five year use
debt fund deal remain pru recent issuanc repres
initi ep estim repres increas
ep accept pru guidanc ep accret iq
addit model expens run-rat margin expans
pru usfw initi unrel assur iq
valuat reiter neutral lower target price target
price base price-to-book roe/co analysi assumpt gener lower
end roe guidanc intermediate-term part due lower interest rate vs
prescrib band risk includ ep miss give full credit
guid usfw deal accret interest rate equiti sensit long-term care
exposur capit intens busi
date product utc date dissemin utc
price month
adjust estim adjust vlo earn estim
vs consensu new estim line buy-sid expect
adjust estim lower reflect lower mid-con earn narrow diff weaker
ethanol margin given improv overal refin macro diesel crack expect
refin estim refin oper incom vs
estim gc oper incom vs estim mid-con
oper incom vs narrow diff estim north atlant
oper incom vs wc oper incom vs
benchmark crack qoq signific improv captur
ethanol estim ethanol oper loss vs incom
higher corn price headwind
renew diesel segment estim renew diesel oper income/
ebitda vs benchmark qoq volum
qoq line guidanc
outlook distil fundament improv believ well posit benefit
imo tailwind canada rail curtail would major posit catalyst
sharehold return estim buyback total
valuat tp base sum-of-the-part methodolog ebitda multipl
refin estimate ethanol segment ebitda
date product utc date dissemin utc
price month
highlight brookfield group held anoth well attend investor day new york citi
present top hous major publicli trade limit partnership
brookfield infrastructur partner lp bip brookfield renew partner lp bep
brookfield properti partner lp bpi bip initi thought day appear
summari note long list posit investor day larg focus posit
deploy capit recycl themat bip extrem well posit on-going
growth multipl vertic stock split new corpor structur may creat
interest support valuat per past work remain focus deploy
recycl across busi per recent investor day outlook note select thought
ahead investor day
select detail takeaway includ deploy recycl good year
thu far prospect happen line broader brookfield fund rais cycl
 debt financ infrastructur asset extrem attract histor context
brookfield look broaden investor base recent announc brookfield
infrastructur corpor bipc structur look posit receiv long
term success themat interest howev clear balanc complex
seen structur past
invest thesi bip well posit within broader brookfield group impress
third parti fund rais along ampl deploy opportun enhanc exist organ
growth profil two major overhang address focu rel valu versu
valuat target price neutral rate bip obtain estim
distribut yield bp spread project us bond yield risk
includ oper level foreign exchang impact regulatori risk
date product utc date dissemin utc
reason less neg janu
henderson meet ceo cfo
last thursday host investor meet janu henderson ceo dick weil cfo
roger thompson firm london headquart follow meet reiter
under-perform rate continu becom less neg stock due reason
estim net outflow improv due lower redempt intech improv us
retail flow increment revenu synergi posit flow fix incom europ
option japan asset manag one relationship look jhg us mutual
fund perform fee posit inflect weak perform rolls-off
calcul total firm perform fee could reach posit scenario
level henderson gener strand alon firm intech
perform improv poor perform rolls-off track
record brexit matter scenario could actual posit even
prepar hard brexit scenario trade discount us uk/eu
aus-bas asset manag stock provid dividend yield dont see
risk continu see invest profession turnov key risk especi two
former senior execut run independ asset manag firm recent em
dont think key prioriti believ larger merger highli
unlik year later larg finish integr merger equal
henderson janu believ could start evalu acquisit candid
dont think firm interest larger/expens redund driven merger addit
firm focus optim streamlin exist capabl includ
harvest revenu synergi hgg-jn merger think firm could look fill
exist traditional/liquid market hole includ emerg market debt us municip via
smaller acquisit bolt-on team lift-out howev dont think firm interest
form anoth separ brand affili would look integr addit busi
janu henderson brand/model
date product utc date dissemin utc
price month
price month
investor day highlight brookfield group held anoth well attend investor day
new york citi present top hous major publicli trade limit
bep brookfield properti partner lp bpi bbu portion day focus
sever area includ approach extract valu portfolio compani capit
alloc principl given go anywher invest approach natur home
unithold still clear continu believ stock period season
wit brookfield lp earli day initi thought day appear
group-wid summari note highlight brookfield-polooza long list posit
investor day maintain prefer bbu within coverag univers view
bbu offer compel valu opportun high qualiti franchis midst season
select detail notabl takeaway includ execut focu deep dive
westinghous clario busi long-term aspir ebitda
respect discuss nut bolt approach drive
valu acquisit ampl liquid bbu deploy potenti view
bbu
invest thesi bbu offer compel valuat misunderstood path surfac
valu abil compound capit outsiz return
valuat target price outperform rate bbu base
includ ev/ebitda multipl infrastructur servic multipl
busi servic blend approach ev/ebitda power solut price-to-earnings
npv brk ambient cf nap industri servic segment risk
rate target includ portfolio compani perform abil deploy capit capit
date product utc date dissemin utc
price month
end-market outlook mix na on-highway sale driven municip
spend tend stabl current inventori retail sale ratio class straight
 class lesser extent elev indic correct may come class
straight volatil greater downsid risk view within na off-highway
remain challeng see risk part relat na energi continu
soft least although comparison eas
better view product novemb custom provid product forecast
follow year
better posit downturn see less downsid ebitda risk assum downturn
given alsn defens mix sale given balanc sheet margin improv
versu previou downturn reduc overtim would first step respons
downturn action alon would suffic assum downturn given
signific downturn alsn next lever pull would reduc headcount current
natur anoth lever could pull downturn replac retire versu
cut headcount bottom line alsn higher peak margin result higher margin
trough view
market outgrowth opportun class market area market
outgrowth gm recent re-ent class market chevi silverado
also target market share class market opportun
penetr market exclus supplier transmiss gm
class addit success grow market share
straight truck market also believ downturn present opportun
custom need appropri weigh invest decis new alt technolog
custom may look outsourc effort better manag return
environ greater spend requir
date product utc date dissemin utc
price month
highlight brookfield group held anoth well attend investor day new york citi
present top hous major publicli trade limit partnership
brookfield infrastructur partner lp bip brookfield renew partner lp bep
brookfield properti partner lp bpi bep initi thought day appear
summari note long list posit investor day larg focus themat
posit renew busi along firm global reach given brookfield broader
success third-parti fund rais posit momentum franchis multipl
respect bep well posit on-going growth multipl vertic stock split
new corpor structur may creat interest support valuat per past
work remain focus deploy recycl across busi per recent
investor day outlook note select thought ahead investor day franchis continu
impress term size scale global reach howev structur differ versu
other sector
select highlight key takeaway includ sweet spot on-going
shift gener mix toward renew themat posit match
brookfield increas fund flow on-going outreach global basi provid transact
opportun underpin organ develop portfolio similar bip brookfield
look broaden investor base brookfield renew corpor bepc
invest thesi regard bep best class develop long-dat renew
power savvi purchas distress asset
valuat target obtain varieti approach includ target
cash-on-cash yield risk includ hydrolog level wind energi level may vari
date product utc date dissemin utc
price month
c-level field point discuss
recent pleasur host ppg michael mcgarri chairman ceo vincent
moral cfo david bem rebecca liebert execut vice presid meet
pittsburgh key takeaway
investor focu address broad rang topic past sever week incl
field investor interest increas dramat key theme includ price/cost
outlook w/ optim resin deflat ii potenti larg small iii
outlook volum given global macro backdrop w/ concern europ china
abund iv statu ppg new product pipelin recent product momentum
hd paint stain investor tone gener construct sinc late aug underscor
optim price/cost benefit augment potenti accret
macro outlook still weigh given volum uncertainti
ppg messag construct uncertainti remain ppg outlook
gener construct indic margin continu improv industri focu
uncertainti global auto build hous gen industri appear
within ppg expect big surpris trend aero refinish price coil
remain construct front optimist broader deal book potenti
continu explor variou opportun stress strong commit financi
return target dedic disciplin also emphas flexibl surround capit
alloc given healthi balanc sheet
price back focu tide favor turn optimist
price cost trend w/ caveat clear price raw stabil probabl deflat
improv tuck-in bolt acquisit margin on-going integr compon
return industri margin back peak perform alreadi well lt clear
dedic continu improv initi esp europ believ
cost issu vs peer one swing factor balanc year extent
china curtail key raw compon overal clearli commit re-achiev
date product utc date dissemin utc
opin open
price month
decis decis market close friday canadian regul cer
releas decis order enbridg inc enb stop current open season process
associ canadian mainlin system docket one
critic passag decis commiss order enbridg may offer firm
servic prospect shipper mainlin firm servic includ associ toll
term condit servic approv commiss clariti effect
order enbridg may continu current open season process simpli
cer express concern area includ concern enb potenti abus
market power potenti cost exist prospect shipper current
environ seri uniqu circumst underpin need cer intervent
view number reason current environ uniqu larg unpreced
translat cautiou regulatori timelin requir ultim believ enb best
posit migrat mainlin contract framework versu period time
last yet process other face signific scrutini
select detail notabl cer letter includ nation energi board
neb receiv four submiss regard enbridg current open season firm servic
mainlin concern fair transpar open season process market
power must allow abus term substanc appear
percept enb domin market posit
invest thesi clear risk exist enb favour wcsb liquid pipelin busi
around approv timelin howev busi well posit growth de-risk
next month
valuat neutral rate target price obtain sever approach
includ impli ev/ebitda multipl price-to-earnings multipl dividend yield
risk target rate includ interest rate regul
date product utc date dissemin utc
price month
lower expect respons rate
present updat data saturday colorect appendic
cancer annual meet european societi medic oncolog esmo
congress barcelona overal orr object respons rate much lower
saw nsclc non-smal cell lung cancer patient high-
dose mg cohort decent diseas control rate across dose level
high-dos patient clear biolog differ lung patient
drive significantli differ clinic result safeti remain consist prior updat
dlt dose-limit toxic serous/fat treatment-rel look forward think
combin therapi mek inhibitor could help improv orr
patient note difficult tumor-typ treat typic orr
patient patient call dr fakih trial present reiter intrins
differ biolog may account differ respons rate lung colorect
tumor mirati share could also impact potenti read-through kra asset
initi data expect still remain posit program
seen rel strong orr name lung sick advanc patient combin
therapi could improv respons rate impact durabl given diverg
lung cohort patient expect potenti weak share
remain posit nsclc potenti combin
monotherapi in-lin outperform thesi data less
impress nsclc remain posit posit nsclc data
potenti util combin somewhat less posit indic
estim could gener peak sale ultim success worth
note modest opportun rel lung assign
valu across indic look next updat phase
monotherapi phase combin data enrol trial on-going
prior work updat world lung
date product utc date dissemin utc
china coal price limit impact
bottom line solar manufactur under-perform last week due concern lower solar
power price china henc lower pricing/gross margin/demand chang
announc benchmark coal power price howev believ under-perform
overdon benchmark power price better fear float adjustor futur
project either grandfath higher price succeed unsubsid price
still await addit clariti formula chang benchmark solar subsidi benchmark
unsubsid power price margin signific reduct power price fear
neg solar manufactur posit solar develop howev among
manufactur see less neg impact manufactur higher exposur us
either lock tariff exempt suppli agreement -n tariff exempt technolog
 o/p follow manufactur higher us mix support suppli constrain
southeast asia manufactur capac jk posit impact technolog agnost solar
happen per media sourc china announc last week would liber coal
electr price could move away current benchmark price float price link
commodity/fuel input later week govern clarifi would transit
control manner benchmark float price higher mix
float variabl thereaft pleas see note china util team detail
market over-react possibl benchmark tariff polici chang renew tariff
uncertainti reduc formal announc benchmark tariff formula chang
impact solar stock china calcul subsidi solar project base
benchmark power price unsubsid project fall benchmark price henc
chang benchmark power price china could potenti impact china solar project irr
modul gross margin demand forecast china solar demand gw
global demand howev benchmark price sustain chang
float adjustor would unlik impact subsidi grid-par timelin project
develop like grandfath prior subsidi chang
benchmark price expect limit impact solar grid pariti countri
moreov expect impact demand estim beyond driven
unsubsid econom anyway solar project unsubsid bid averag price
rmb low rmb vs averag
benchmark coal-fir tariff rmb rang rmb longer
term see addit opportun solar power output price declin due module/system cost
date product utc date dissemin utc
pemex revis factor use maya price formula month
octob factor month septemb would lower
month octob chang lead meaning increas discount maya price
crude benefit gulf coast refin maya usgc hsfo ll
drove chang believ number factor involv forc pemex hand
lower factor therebi rais maya price discount us refin first last month
pemex rais factor result materi compress brent-maya
discount put maya coke econom seriou pressur pemex would
encourag gulf coast refin substitut maya crude global heavi sour barrel
result loss market share second week alberta govern announc
roll back mandat cut month dec allow increment heavi
barrel come market year end year-end alberta mandat cut would drop
vs start year jan third report alberta
govern close approv rail curtail deal would allow curtail
volum come on-line long increment volum sold provinc alberta
fourth process facil still saudi suppli heavi barrel
custom vs light barrel chang temporari would also taken
consider pemex decid factor month octob
view maya price said past imo world maya price
discount significantli higher resid yield drive wider crude discount maya crude
last week dinner event manag indic global ship industri could
run complaint fuel month novemb could rise
month decemb would impli fuel oil price make anoth sharp downward
move us refin coke hydrocrack desulfur capabl high nelson
complex would still abl process sour maya barrel global demand crude
come pressur pemex much better work us refin tri
squeez risk lose market share canadian produc su cnq cve imo
hse got extrem flexibl refin system also
got strong trade team last week canada energi regul report crude-
by-rail export averag juli june rail ramp alberta
forc maya price competit risk meaning loss market share
stock thought brent-maya spread current believ revis
factor kick oct brent-maya widen least put maya coke
econom back green wider heavi sour spread gulf coast signific
earn tailwind
date product utc date dissemin utc
cs global pharma biotech
zolgensma learn fda
patient switch appear occur report earli
septemb list total case report fda patient case
also take spinraza unclear report patient switch
spinraza zolgensma use therapi combin recent expert discuss
suggest like former written previous believ zolgensma
attract differenti spinraza term efficaci toler standpoint
chronic spinal infus difficult endur convers infant sma market
zolgensma necessarili unexpect result speak well potenti opportun
roche/ptc risdiplam convert portion exist spinraza market expect risdiplam
daili oral medic approv next year envis strong uptak larger
preval type sma popul expect risdiplam achiev
global sale assum peak sale across rang sma type
age novarti zolgensma account per share total npv assum
peak sale risdiplam roch model account around total
npv interact model detail
risk/benefit proposit overal zolgensma safeti profil track similar
observ clinic studi liver enzym elev drop platelet count
troponin elev patient die due treatment view
overal result accept light potenti robust efficaci support
import risk/benefit calcul administ high dose gene therapi choos
indic high unmet need especi critic gene therapi expect dose
vg/kg rang separ result reinforc view least high dose
gene deliveri vehicl use zolgensma potenti capsid carri
risk immun system/compl activ issu observ pfe
sldb dmd gene therapi studi program use srpt dmd program
use capsid demonstr compar better ae profil far though
present data limit four patient
date product utc date dissemin utc
candid note call renew zero-carbon emiss electr
gener carbon neutral pledg invest trillion
procur american-mad clean energi product plu anoth project
develop subsequ export result technolog
countri sever forward-lean util pledg carbon full coal retir
ni carbon neutral see
realist implement warren plan necessarili involv major step regul
electr util invest current plan support ep growth also highlight
nee heavi exposur utility-scal renew growth illustr chart
regul electr outperform safeti play year support low bond
yield see trend continu least unless monetari inflat
higher rate materi interfer fundament tailwind estim annual net util
capital-expenditure across industri increment renew
support infrastructur nomin renew growth rate could rise substanti
warren plan see recent sector valuat note detail
take renew week start busi day investor corpor
meet solar trade show utah near-term demand uncertainti china still unchang
investor focus company/sector expect ahead quiet
period pleas see take-away note detail week end uncertainti
china move liber power tariff better fear float adjust
believ limit impact long term subsidi free demand
date product utc date dissemin utc
still point stabil
august gener deflat trend mix base analysi total gener drug sale
report iqvia unweight basi sell-sid asp gener therapeut fell
august sequenti improv declin juli exclud ltm new gener
launch meanwhil sales-weight basi metric indic declin august
compar experi juli accord juli nadac data publish
septemb survey perform gaug averag nation acquisit cost
retail pharmaci across us report gener experienc price declin
excess juli repres improv june experi well
broadli improv trend y/i context on-going gener price deflat past two year
consist tracker weigh drug distributor price declin led lower
gross profit dollar expect meaning revers near term
encourag seemingli stabil trend
methodolog analysi calcul total gener sale data report iqvia divid
total associ unit defin iqvia manufactur ship packag gener proxi
gener prescript asp help address lag two month well smaller
scope dispens channel nadac data exclud ltm gener launch said
continu view nadac import supplement analysi
suppli chain read-through consist analysi highlight recent commentari
industri constitu suggest overal stabil gener price
pressur greater visibl drug price could indic potenti relief lead drug
distributor howev on-going
tough util environ broader brand drug price uncertainti continu
overhang favor best posit drug distributor greater
exposur faster grow profit non-tradit busi may help mitig
on-going headwind note accord iqvia total prescript sale increas
august deceler juli trend character increas brand sale
declin gener sale
date product utc date dissemin utc
med-tech recap preview
new robot hit
mark tct reinforc confid tavr
tct posit tavr mitral stori evolv clinic session check
clinician transcathet cardiovascular therapeut meet point continu strong
growth tavr mitral repair replac technolog continu progress begin fill
slot toolbox host analyst brief reinforc respect
pipelin next mo host conf call discuss take-away
et see page dial-in detail
robot surgeri system unveil solid posit
compet robot soft-tissu spine surgeri respect stock under-perform
post present view robot key intermedi long-term driver nass
also featur new product innov overweight-r
well underperform-r
jnj score win darzalex erleada detail data due upcom
idweek darzalex receiv fda approv use combin bortezomib thalidomid
dexamethason vtd newli diagnos patient multipl myeloma elig autolog
stem cell transplant asct addit phase spartan trial posit show
erleada demonstr reduct mortal risk patient non-metastat castration-
resist prostat cancer nmcrpc vs placebo see page detail detail result
long-act combo inject hiv also expect idweek washington dc
ytd bp bp ms ltm
vs ms led group week ew
lead ytd lc growth diversifi ms ntm ev/
ebitda respect vs
date product utc date dissemin utc
bottom line report aug total semi m/m
season m/m aug semi ex-memori m/m
season august mark second consecut month above-season
trend semi ex-memori data continu suggest bottom semi specif
semi ex-memori decreas y/i compar may/june/juli declin
growth still neg though deceler season growth indic y/i
growth trough june absolut trough feb durat ppt p-t
declin compar cycl averag month ppt albeit t-p growth
last upturn roughli half averag impli depth/dur line prior cyclic
correct assum season growth sep would impli ex-memori growth q/q
ahead street estim q/q lastli track y/i slightli
better cs/street y/i data continu suggest bottom
process semi two key risk still loom china/u trade uncertainti specif whether
suppli chain pull forward demand minim impact addit tariff increas
would highlight outsiz demand hisilicon crypto appl suppli chain overal
macroeconomic concern especi light recent invert yield curv bia
construct hard cyclic bottom certainti depth/dur metric
support importantli secular thesi remain much intact semi move
minu plu growth sce cyclic growth cyclic data
driven economi repres growth option net/net see lt semi compound-annual-growth-rate improv
least option would highlight follow sia
fourth consecut month y/i growth sinc declin averag y/i
prior current cycl dram bit declin dram
declin m/m y/i increas m/m juli decreas
last month peak month fallen
compar averag durat month
nand bit strong stabil aug nand bit grew y/i price elast
continu drive strong bit demand sinc y/i nand bit growth averag
lt demand growth declin y/i continu y/i declin
start though increas m/m first posit chang sinc
assum season asp growth data would impli asp trough nand
peak month ago compar averag cycl peak
trough depth/dur
date product utc date dissemin utc
august rx sale trend increas accord restat metric iqvia monthli
total prescript sale rose y/i august includ increas brand
declin gener prescript sale latest trend repres deceler
torrid experi juli albeit respect trend
data point suppli channel momentum total prescript sale temper august
follow solid juli experi brand strength continu offset declin gener
sale low growth backdrop focu capit effici suppli chain
compani diversif strategi build growth driver outsid tradit suppli
rx volum tick higher august accord previous releas volum metric iqvia
august prescript volum increas character increas gener
decreas brand prescript
date product utc date dissemin utc
evan weekli dose therapi
weeka busi week esmo
esmo compani present new data expect
updat posit disclos major patient report
go forward treat mg dose believ expect modest
limit respons rel nsclc seen though modest
opportun rel lung data may posit read-through broader program dial-in
link esmo preview
esmo present posit updat pemigatinib cholangiocarcinoma bile
duct cancer pemigatinib monotherapi continu show strong efficaci orr primari
endpoint month compar favor month seen standard
chemo dcr median dor month os month find data
compel note pemigatinib compet directli js balversa uc
make commerci difficult note follow-up
mirati adjust model ahead present esmo lower
tp moder market assumpt sitravatinib
present weekend may valid kra druggabl target
mirati stock histor react readout present
may wclc sep initi data expect possibl tripl
aacr-nci-eortc meet octob mirati schedul present link note
regeneron announc friday oral inhibitor abrocitinib potenti
competitor regeneron dupix met trial co-primari endpoint patient older
moder sever atop dermat efficaci abrocitinib could potenti
compar dupix mani question remain whether abrocitinib safe enough
formid competitor see potenti abrocitinib compet regeneron dupix
ad data strong safeti benign expect intensifi competit ad next
year novel jak inhibitor abrocitinib upadacitinib novel biolog link
neurocrin compani initi phase trial ingrezza huntington chorea
current assign valu indic somewhat cautiou ingrezza fail
tourett howev note teva austedo also inhibitor current approv
huntington chorea black box increas risk depress suicid ideat
indic expans without black box may signific point differenti consensu
forecast austedo sale
compani announc first patient treat phase true-v clinic trial program
evalu ruxolitinib cream monotherapi adolesc adult patient age year
vitiligo encourag progress topic ruxolitinib vitiligo patient
continu believ high-unmet need vitiligo
date product utc date dissemin utc
food thought alexa may take
weekli us restaur note highlight signific news pertain
coverag industri
oper digit takeaway industri event
week attend cohnreznick restaur technolog summit heard
restaur oper servic provid tech compani sentiment posit
expect industri appear embrac digit transform explor
opportun creat valu data key topic focu restaur look enhanc
infrastructur better captur analyz data inform decis discuss confer
also highlight advanc voic technolog expect first use drive-
thru larger scale like integr restaur time
also attend restaur start-up event sentiment cautiou early-stag
investor small restaur oper highlight challeng oper digit age
lower expect on-going restaur level margin given increment tech cost small
restaur oper seem view beneficiari emerg technolog
note third-parti deliveri necessari access larg unprofit limit opportun
take advantag turnkey solut like ghost kitchen large/establish brand
mcdonald announc join plant-bas protein convers test
beyond meat launch stand plant lettuc tomato
restaur ontario start unlik competitor referenc
beyond brand part new menu name like test viabil demand plant-bas
protein reserv option diversifi differ vendor beyond brand
featur part pop display restaur local menu advertis ingredi
list note test allow compani gather feedback custom demand
measur impact oper evalu suppli chain implic
week restaur
coffe carib coffe deal bojangl size coffe friday nation
day bell nation day gift set four icon taco
notabl news restaur
inspir brand announc enter agreement acquir jimmi john landri
announc enter agreement acquir del frisco doubl eagl steakhous del
frisco grill catterton launch test
restaur ontario start sweetgreen close fund round bring
valuat dol announc final rule overtim pay rais standard
salari level effect
date product utc date dissemin utc
someth chew foodservic
vice versa
name within coverag univers lower averag week driven food
retail dollar store food distributor vs xrt
xlp wed also highlight industri focus choppi trade
week manag team present competitor confer provid
notabl intra-quart updat highlight solid trend truli independ local case
despit continu pressur within local/region chain captur local microchain
regard price competit clarifi remain disciplin winning/
retain busi chain size wherea reiter ebitda growth guidanc
larg line cautiou around independ case growth indic
saw modest slowdown within independ middl across sever geographi
due weather time custom on-board etc factor anticip
bp impact ind growth expect independ case growth
toward lower end quarter healthcar hospit expect
case growth lower end rang note lose larger custom
competitor see independ case growth ebtida growth fairli solid
base busi continu trade discount peer
highlight week news flow
amazon expand two-hour whole food deliveri catch bloomberg
take amazon began test person whole food promot entic prime member
use two-hour deliveri offer use in-stor purchas data prime member citi
send target offer show previou in-stor whole food purchas
websit addit wherea whole food custom abl search deliveri
offer prime app previous offer servic main site
capit million uniqu monthli visitor visit websit continu
integr whole food core oper effort grow groceri sale
competit remain fierc kr smaller player focus expand
same-day groceri deliveri roll groceri pickup begin matur lean
heavili exist grocery-focus loyalti card data time like instacart
peapod ahold delhaiz increment focus groceri pickup
meat get pricier china peckish protein wsj
take price meat includ beef poultri pork increas around globe
larg driven increas demand china heel african swine fever asf
concern impact pork suppli china pork consumpt doubl europ
 combin china meat import surg asf hit hog farm across china
reduc domest suppli wherea american shopper thu far havent felt much price
impact china meat purchas yet august cpi note could soon chang indic
august food ppi show first sign pork inflat december-d hog futur
far month said yesterday there inflat isol
categori bacon industri expect see materi impact next
coupl quarter said indic restaur gener flexibl
around inflat particular protein categori compani highlight abil
pass cost
date product utc date dissemin utc
crude natur ga fall oil price fell report
saudi product restor closer pre-attack level faster skeptic
anticip addit recov suppli outlook demand resurfac concern
forefront trump impeach hear percept intensifi us-china trade
disput hurt global demand outlook weak industri demand figur report host
countri iea say may cut demand forecast global econom
weak persist natur ga fell close bcf storag
inject ahead bcf consensu reflect materi loosen weather-
 ps under-perform broader market xop fell under-perform
 fell
compani news week host ps/major annual non-bu tour
houston midland takeaway includ compani highlight soften servic cost
particularli permian consider focu reduc activ put oil volum
risk perceiv investor skeptic around abil slow-growth strategi actual
drive attract yield oil price suggest ralli crude necessari
attract generalist interest space compani highlight consid ex-growth
plan weak oil price scenario highlight de-rat permian
equiti make valuat attract will chase deal infer capital-expenditure
modestli lower yoy spud first explor well surinam provid
visibl well cost reduct delawar cost still peer
believ could gener slight dividend even ga price
like investor constitut pipelin clarifi capital-expenditure yoy
trend lower discuss attract ef acquisit opportun given near-pdp
valuat emphas gener key program discuss
 cut save eca signal modest long-term liquid growth goal
gener oil price news sale oxi mozambiqu asset
tot close earli next week algeria ghana asset expect close
end earli asset part apc deal announc surpris
asset sale program aim bring leverag end
announc tender convert debt close oversubscrib accept
look week ahead monday expect product data juli show
mbbld mom declin driven hurricane-rel downtim still mmbbld yoy
expect data show us natur ga product rose mmcfd bcfd
yoy forecast eia report bcf natur ga storag inject thursday
date product utc date dissemin utc
lean weekend
week global user exchang recap shaw said take activ stake
per reuter weftec feedback involv lummu asset sale back
week macro sept consum confid vs consensu aug
 eurozon sept econom sentiment indic vs consensu
 eurozon sept industri confid vs consensu aug
china beig book highlight economi weakest year
manufactur properti servic sector worsen even borrow pick
tokyo sept cpi y/i vs consensu aug japan sept flash
pmi fell vs consensu
follow week us-china trade talk dc
digit transform evolut global user forum takeaway week
attend emr global user exchang nashvil alongsid custom theme
tune part mix first time attende statist enforc
emr portfolio broaden beyond process instrument engin
profession hybrid market next gener custom purpos
event showcas new technolog interact custom pick posit
activ larger capit decis remain paus potenti exist link note
date product utc date dissemin utc
